Guo Zhi, Yu Haipeng, Liu Changfu, Si Tongguo, Yang Xueling, Zhang Weihao, Xu Yan, Li Yong
Department of Interventional Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Cancer Research Center, Key Laboratory of Cancer Prevention and Therapy.
Drug Discov Ther. 2015 Oct;9(5):342-51. doi: 10.5582/ddt.2015.01057.
Transcatheter arterial chemoembolization (TACE) is a minimally invasive procedure to restrict a tumor's blood supply, and TACE has an established role in cancer therapy. An embolic material in the form of microspheres (such as drug-eluting beads) and transarterial radioembolization is effective at treating hepatocellular carcinoma (HCC). Endovascular therapy offers promise for the treatment of tumor thrombi in the portal vein. Many researchers are anticipating an era of TACE with microspheres. This review aims to provide an overview of advances in endovascular therapy to treat primary HCC.
经动脉化疗栓塞术（TACE）是一种限制肿瘤血液供应的微创手术，在癌症治疗中已确立了其作用。微球形式的栓塞材料（如载药微球）和经动脉放射性栓塞术在治疗肝细胞癌（HCC）方面有效。血管内治疗为门静脉肿瘤血栓的治疗带来了希望。许多研究人员期待着微球TACE时代的到来。本综述旨在概述治疗原发性肝癌的血管内治疗进展。
